A day after the Serum Institute of India (SII) used to be issued a show cause notice by the Drugs Controller General of India (DCGI), it said it used to be pausing Covid-19 vaccine trials in the country.
“We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials. We are following Drug Controller General of India’s (DGCI) directions and won’t be able to remark further on trials,” SII said.
DGCI issued the notice to the Serum institute for not informing them approximately AstraZeneca pausing the clinical trials in other countries and for not submitting casualty analysis of the “reported serious adverse events”.
The SII is manufacturing Oxford University’s Covishield vaccine in collaboration UK-based pharma giant AstraZeneca.
AstraZeneca paused the trials of the vaccine on Sept 8 after one of its recipients in the UK developed an ‘unexplained illness’.